10-K: Jazz Pharma's 2025 10-K: Strong Oncology & Epilepsy Growth

Jazz Pharmaceuticals plc reports a 5% increase in total revenues for 2025, driven by strong growth in rare oncology and epilepsy products, despite declines in oxybate sales due to generic competition.

Summary

• Total revenues increased by 5% to $4,267.6 million in 2025, up from $4,069.0 million in 2024.
• Net product sales increased by 5% to $4,021.8 million in 2025.
• Xywav net product sales grew by 12% to $1,657.0 million in 2025, with approximately 16,175 patients (10,950 narcolepsy, 5,225 IH).
• Epidiolex/Epidyolex net product sales increased by 9% to $1,059.2 million in 2025.
• Modeyso, approved in August 2025, generated $48.0 million in sales.
• Ziihera, launched in December 2024, generated $24.8 million in sales.
• Zepzelca sales decreased by 4% to $307.3 million in 2025, impacted by increased competition.
• Rylaze sales decreased by 2% to $402.9 million in 2025, affected by pediatric treatment protocol updates.
• Xyrem net product sales decreased by 38% to $146.0 million in 2025 due to high-sodium oxybate competition and Xywav adoption.
• High-sodium oxybate AG royalty revenue decreased by 3% to $211.7 million in 2025.
• Net loss for 2025 was $356.1 million, compared to net income of $560.1 million in 2024, primarily due to litigation settlement expenses and acquired in-process research and development (IPR&D).
• Selling, general and administrative expenses increased by 31% to $1,809.3 million in 2025, including $233.5 million for Xyrem antitrust litigation settlements and $90.0 million for Avadel litigation settlement.
• Acquired IPR&D expense was $947.9 million in 2025, mainly from the Chimerix Acquisition ($905.4 million) and Saniona licensing ($42.5 million).
• Cash flow from operations was $1,355.8 million in 2025.
• Total debt as of December 31, 2025, was approximately $5.4 billion.
• The company completed the Chimerix Acquisition in April 2025 for $944.2 million cash.
• Divested Sativex to CNX Therapeutics in October 2025.
• Sold a rare pediatric disease Priority Review Voucher (PRV) in January 2026 for $200.0 million, with 50% attributable to the company.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing with significant one-time legal expenses leading to a net loss, and ongoing challenges from generic competition for key products, partially offset by strong growth in newer oncology and epilepsy assets and pipeline progress.

Positives

• Total revenues increased by 5% in 2025, demonstrating overall business growth.
• Xywav sales increased by 12% in 2025, driven by increased volumes and adoption in both narcolepsy and idiopathic hypersomnia (IH).
• Epidiolex/Epidyolex sales increased by 9% in 2025 due to increased demand and geographic expansion.
• Successful launches of new rare oncology products: Modeyso ($48.0 million in 2025) and Ziihera ($24.8 million in 2025).
• Ziihera received accelerated FDA approval in November 2024 and conditional marketing authorization from the EC in June 2025 for HER2-positive BTC.
• Modeyso received accelerated FDA approval in August 2025 as the first and only treatment for diffuse midline glioma with an H3 K27M mutation.
• Zepzelca received FDA approval in October 2025 for a new first-line maintenance treatment indication in extensive-stage SCLC.
• Positive top-line results from the Phase 3 HERIZON-GEA-01 trial for zanidatamab in HER2-positive GEA, showing statistically significant and clinically meaningful overall survival and progression-free survival benefits.
• FDA granted Breakthrough Therapy Designation (BTD) for zanidatamab in HER2+ unresectable locally advanced or metastatic GEA.
• Generated $1.36 billion in cash flow from operations in 2025.
• Reversal of a valuation allowance against certain U.S. federal and state deferred tax assets acquired through the Chimerix Acquisition, resulting in a $212.5 million deferred tax asset recognized.
• Successful resolution of the Xyrem Antitrust Litigation and Avadel Litigation in 2025.
• Extension of Hikma AG product sales period until December 31, 2029, with continued meaningful royalty payments.
• Maintained effective internal control over financial reporting as of December 31, 2025.

Negatives

• Net loss of $356.1 million in 2025, a significant reversal from net income of $560.1 million in 2024.
• Xyrem product sales decreased by 38% in 2025 due to high-sodium oxybate competition and Xywav adoption.
• Zepzelca product sales decreased by 4% in 2025 due to increased competition in second-line SCLC and treatment protocol updates.
• Rylaze/Enrylaze product sales decreased by 2% in 2025, impacted by updates to pediatric treatment protocols for ALL.
• Significant increase in selling, general and administrative expenses by 31% in 2025, largely due to $233.5 million in Xyrem antitrust litigation settlements and $90.0 million for the Avadel litigation settlement.
• High acquired in-process research and development (IPR&D) expense of $947.9 million, primarily from the Chimerix Acquisition.
• Substantial debt of approximately $5.4 billion as of December 31, 2025, which could impair flexibility and access to capital.
• Exposure to foreign currency exchange rate fluctuations, which adversely affected net income in 2025.
• Ongoing competition for oxybate products from generic versions and branded alternatives like Lumryz.
• Potential for increased tariffs on pharmaceutical imports, which could increase costs and disrupt the supply chain.
• Reliance on single-source suppliers for most products and APIs, posing a risk of supply interruption.
• WuXi (Hong Kong) as the sole supplier of Ziihera, with potential risks from PRC regulatory and political structure, including the BIOSECURE Act.
• Patheon's intent to terminate the Rylaze manufacturing agreement effective end of 2026.
• Modeyso is manufactured by Adare, a sole source supplier.
• Defitelio is manufactured by Patheon, a sole source supplier for finished vial form, and the company is the sole worldwide producer of defibrotide API.
• Legal challenges to FDA's orphan drug exclusivity policies, which could affect product protections.
• The OBBBA (One Big Beautiful Bill Act) signed in July 2025 is anticipated to decrease federal healthcare spending, potentially reducing access to and reimbursement for products.
• Increased scrutiny on drug pricing practices and potential for Most-Favored-Nation (MFN) pricing models, which could reduce U.S. drug prices and impact profitability.
• The U.S. Supreme Court's Loper Bright decision in June 2024 reduced judicial deference to regulatory agencies, potentially increasing legal challenges to federal regulations.
• The new EU pharmaceutical legislation (provisional agreement in December 2025) could impact the scope and duration of market and orphan exclusivities and require meeting certain access obligations.
• The company has never declared or paid dividends and does not anticipate doing so in the foreseeable future.

Risks

• Inability to maintain revenues from the oxybate franchise due to competition from generic versions of high-sodium oxybate (e.g., Amneal, Ascent) and branded products (e.g., Alkermes' Lumryz).
• Significant regulatory restrictions on oxybate products, including REMS requirements, which could negatively impact sales or lead to enforcement actions.
• Inability to maintain or increase sales of Epidiolex/Epidyolex due to competition from generic cannabinoids and non-FDA approved CBD preparations.
• Substantial competition from other companies with larger sales organizations and diverse product portfolios, and from generic drugs across the portfolio.
• Inadequate coverage and reimbursement from third-party payors, including PBMs, potentially requiring significant rebates or discounts.
• Increased scrutiny on pharmaceutical product pricing and changes in healthcare law and policy (e.g., IRA, OBBBA, MFN pricing models) impacting business and financial condition.
• Delays or problems in the supply of products for sale or clinical trials, loss of single-source suppliers, or failure to comply with manufacturing regulations.
• Global trade issues, changes in trade policies, export regulations, sanctions, and tariffs (e.g., BIOSECURE Act impacting WuXi) increasing costs and reducing competitiveness.
• Failure to realize anticipated benefits from the Chimerix Acquisition, including Modeyso's commercial success.
• Inability to successfully obtain and maintain regulatory approvals for late-stage product candidates or to launch and commercialize them effectively.
• Difficulty in identifying and acquiring or in-licensing additional products or product candidates to grow the business.
• Costly and time-consuming clinical trials with uncertain outcomes, potentially failing to prove safety and efficacy or support indication expansion.
• Challenges in protecting proprietary rights, including patent litigation, invalidation of patents, or third-party infringement claims.
• Significant disruptions of information technology systems or data security incidents, including those enhanced or facilitated by AI.
• Ongoing regulatory obligations and oversight, potentially leading to civil or criminal proceedings, investigations, or penalties.
• Failure to comply with reporting and payment obligations under government pricing programs (Medicaid Drug Rebate Program, 340B, FSS, Tricare) leading to penalties or exclusion.
• Substantial debt ($5.4 billion) impairing financial flexibility and access to capital, and risks related to servicing debt obligations and covenant compliance.
• Need to commit substantial resources for business growth, potentially leading to future losses or limiting opportunities.
• Future impairment of significant intangible assets and goodwill.
• Adverse effects from foreign currency exchange rate fluctuations.
• Changes in effective tax rates due to tax law changes (e.g., Pillar Two, IRA) or challenges from taxing authorities.
• Potential for the IRS to treat the company as a U.S. corporation for tax purposes under Section 7874.
• Limitations on the ability to use Net Operating Losses (NOLs) and carryforward tax losses.
• Volatility in the market price of ordinary shares.
• Irish law differing from U.S. law, potentially affording less protection to security holders.
• Anti-takeover provisions in articles of association, Irish law, and debt agreements.
• Potential dilution from future sales and issuances of ordinary shares or convertible securities.
• No anticipated dividends in the foreseeable future.
• Product liability claims and recalls.
• Risks related to hazardous materials in manufacturing facilities.
• Risks associated with the adoption of AI technologies, including inaccuracies, biases, and cybersecurity vulnerabilities.
• Disruptions at FDA, SEC, and other government agencies due to workforce reductions, inadequate funding, or government shutdowns.
• Risk of litigation or investigations related to workforce initiatives (e.g., diversity, equity, and inclusion).
• Vulnerability to shareholder activism or hostile bids.

Future Outlook

The company expects total revenues in 2026 to increase compared to 2025, driven by continued growth in its rare oncology and epilepsy products, specifically Modeyso, Ziihera, and Epidiolex/Epidyolex. This growth is anticipated to be partially offset by a reduction in oxybate revenues due to decreased high-sodium AG royalties and Xyrem revenues following the launch of multiple generic high-sodium products. Cost of product sales in 2026 is expected to be in line with 2025, while selling, general and administrative expenses are projected to decrease primarily due to the absence of the significant litigation settlement expenses incurred in 2025. Research and development expenses are expected to increase in 2026, driven by ongoing and new clinical studies for zanidatamab and dordaviprone, as well as preclinical and early clinical programs. The company believes its existing cash, cash equivalents, investments, and available funds under its Amended Revolving Credit Facility will be sufficient to fund operations and meet existing obligations for the foreseeable future. For longer-term growth, the company plans to commit substantial resources to product acquisition, in-licensing, product development, clinical trials, and expansion of commercial, development, and manufacturing operations, and expects to opportunistically seek additional capital.

Management Comments

• Our purpose is to innovate to transform the lives of patients and their families.
• We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options.
• Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics.
• We view the continued adoption of Xywav in narcolepsy as a positive indication that physicians and patients appreciate the benefits of a low-sodium oxybate option.
• Our commercial efforts are focused on educating patients and physicians about the lifelong impact of high sodium intake, and how the use of Xywav enables them to address what is a modifiable risk factor.
• We developed Rylaze to address the needs of patients and health care providers for an innovative, high-quality erwinia asparaginase with reliable supply.
• Our strategy for growth is rooted in executing commercial launches and ongoing commercialization initiatives, advancing robust R&D programs and delivering impactful clinical results, effectively deploying capital to strengthen the prospects of achieving our shortand long-term goals through strategic corporate development, and delivering strong financial performance.
• We focus on rare diseases, which often have high unmet needs and small patient populations, resulting in efficient, concentrated call points.
• We seek to identify and develop highly differentiated therapies for these patients that we expect will be long-lived assets and that we can support with an efficient commercialization model.
• We believe that our existing cash, cash equivalents and investments balances, cash we expect to generate from operations and funds available under our Amended Revolving Credit Facility will be sufficient to fund our operations and to meet our existing obligations for the foreseeable future.

Industry Context

StockSavvy.ai notes that Jazz Pharmaceuticals plc operates within a highly competitive biopharmaceutical industry, particularly in rare diseases, oncology, epilepsy, and sleep disorders. The company's strategy to diversify its revenue away from its legacy oxybate franchise is a common industry trend as patents expire and generic competition intensifies. The focus on rare diseases with high unmet needs aligns with a broader industry shift towards specialized therapies, which often command premium pricing and benefit from orphan drug designations, providing extended market exclusivity. The increasing regulatory scrutiny on drug pricing, as evidenced by the IRA and potential MFN pricing models, represents a significant headwind for the entire pharmaceutical sector, potentially impacting profitability and global pricing strategies. The company's proactive engagement in patent litigation and settlements reflects the intense intellectual property battles common in the pharmaceutical space, especially for high-value drugs. The adoption of AI technologies is an emerging trend across the industry, aiming to enhance R&D and operational efficiency, but also introducing new regulatory and cybersecurity risks.

Corporate Governance

Legal Proceedings

• Xyrem Antitrust Litigation: Resolved as of October 2025. Jazz Ireland entered a class settlement agreement with indirect Xyrem purchasers for $145.0 million. Also settled with United Healthcare, Federal Opt-Out Plaintiffs, and Aetna. The company denies all alleged wrongdoing.
• Avadel Litigation: Resolved as of October 21, 2025. Global settlement agreement with Avadel (now Alkermes subsidiary) to settle all claims, including patent infringement suits and counterclaims. Jazz granted Avadel licenses for Lumryz for Narcolepsy Indications (effective immediately) and Non-Narcolepsy Indications (effective March 1, 2028). Avadel to pay royalties of 3.85% (potentially 3.75%) on Lumryz net sales for Narcolepsy Indications from October 1, 2025, and 10% (potentially 9.5%) for Non-Narcolepsy Indications from March 1, 2028. Jazz paid Avadel $90.0 million and waived certain past royalties.
• Xywav Patent Litigation: Ongoing. Lupin, Teva, and Granules filed ANDAs for generic Xywav. Jazz filed patent infringement suits against them in the U.S. District Court for the District of New Jersey. Expects 30-month FDA stay on ANDA approvals. Lupin received tentative approval for its generic Xywav application on October 13, 2023.
• Zepzelca Patent Litigation: Ongoing. Zepzelca ANDA Filers (including InvaGen, CIPLA, Zydus, RK Pharma, MSN) filed ANDAs for generic Zepzelca. Jazz and PharmaMar filed patent infringement suits. Expects 30-month FDA stay. Sandoz lawsuit dismissed without prejudice. RK Pharma remains a defendant in NJ litigation.
• Defitelio Patent Litigation: Ongoing. Almaject filed an ANDA for generic Defitelio. Jazz filed a patent infringement lawsuit against Almaject in April 2025. Expects 30-month FDA stay.
• Tris Pharma Patent Litigation: Initiated in January/February 2026. Tris Pharma filed Section 505(b)(2) NDAs for generic Xyrem and Xywav. Jazz filed two patent infringement suits. Expects 30-month FDA stay.
• FDA Litigation (re: Lumryz): Resolved. Jazz's complaint against FDA regarding Lumryz approval and ODE was denied by the U.S. District Court for the District of Columbia, and the D.C. Circuit affirmed the ruling on June 27, 2025.
• Qui Tam Matters: Whistleblower lawsuit filed in U.S. District Court for the District of Massachusetts unsealed in July 2024, alleging improper marketing activities. Jazz's motion to dismiss federal claims with prejudice and state-law claims without prejudice was granted on September 23, 2025. Another lawsuit filed in January 2026 in New York state, repeating similar allegations, which Jazz will vigorously defend.
• Chimerix Acquisition Litigation: Resolved. Lawsuits alleging omitted material information and misrepresentations in Tender Offer Documents were dismissed after Chimerix filed an amended Recommendation Statement and Jazz filed an amended Tender Offer Document with supplemental disclosures.

Stakeholder Impact

• Shareholders: Impacted by a net loss in 2025, share repurchases, and potential dilution from future capital raises. Benefit from successful product launches and R&D progress. The market price of ordinary shares is expected to remain volatile.
• Employees: Benefit from workforce initiatives focused on culture, engagement, growth, development, and competitive compensation and benefits. Potential exposure to litigation risk related to workforce initiatives.
• Patients: Benefit from new life-changing medicines for rare diseases (e.g., Modeyso for diffuse midline glioma, Ziihera for BTC, Xywav for IH). Access to products may be impacted by pricing and reimbursement policies.
• Customers (Wholesalers, Pharmacies, Hospitals): Affected by product supply, pricing, and distribution agreements. The company's reliance on single-source suppliers poses a risk to consistent supply.
• Creditors: Impacted by the company's substantial debt ($5.4 billion) and the covenants in its credit agreements, which restrict financial flexibility.

Next Steps

• Continued commercialization of Xywav, Epidiolex/Epidyolex, Ziihera, Modeyso, Zepzelca, and Rylaze.
• Advancing robust R&D programs and delivering impactful clinical results for pipeline candidates.
• Identifying and acquiring novel product candidates and approved therapies.
• Building an efficient and productive development engine.
• Unlocking further value through indication expansion and entry into global markets.
• Conducting Phase 3 HERIZON-BTC-302 confirmatory trial for Ziihera in BTC.
• Conducting Phase 3 ACTION confirmatory trial for Modeyso in diffuse midline glioma.
• PharmaMar conducting a confirmatory trial for Zepzelca in second-line SCLC.
• Ongoing Phase 1 study for JZP815 in advanced/metastatic solid tumors.
• Ongoing Phase 1 study for JZP898 in advanced/metastatic solid tumors.
• Initiated Phase 1b study of Epidiolex for focal-onset seizures.
• Monitoring developments and evaluating potential impacts of Pillar Two tax rules.
• Monitoring changes in U.S. and foreign government trade policies and tariffs.
• Seeking further share issuance and pre-emption authorities from shareholders.
• Potential for additional lawsuits related to generic versions of Xywav, Zepzelca, and Defitelio.
• Tris Pharma patent infringement suits filed in February 2026.
• Lonza AG to begin commercial supply of Ziihera in the U.S. beginning in 2029.
• Patheon to terminate Rylaze manufacturing agreement effective end of 2026, requiring a new supplier.

Key Dates

Recommendation

The company faces significant headwinds from generic competition impacting its legacy oxybate franchise and incurred substantial one-time litigation settlement expenses, leading to a net loss in 2025. However, strong growth in newer rare oncology and epilepsy products (Xywav, Epidiolex, Ziihera, Modeyso) and a robust R&D pipeline with positive clinical trial results (zanidatamab in GEA) indicate future growth potential. The successful resolution of major antitrust litigation removes a significant overhang. The substantial debt and ongoing competitive and regulatory pressures warrant a cautious approach, suggesting a 'Hold' recommendation as the company navigates these transitions and aims to diversify its revenue base.

Keywords

Biopharmaceutical, Rare Disease, Oncology, Epilepsy, Sleep Disorders, Xywav, Epidiolex, Ziihera, Modeyso, Zepzelca, Rylaze, 10-K, Financial Results, Drug Development, Regulatory Approval, Patent Litigation, Generic Competition, Healthcare Policy, Debt, Share Repurchase, R&D Pipeline, Corporate Governance, Risk Management, Chimerix Acquisition, Antitrust Litigation